PMWC 2019 Silicon Valley
Luminary & Pioneer Awards

The PMWC Luminary Award recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinical marketplace. The PMWC Pioneer Award is given to rare individuals who presaged the advent of personalized medicine when less evolved technology and encouragement from peers existed, but still made major advances in the field.

This year, for the Luminary Award, PMWC will be honoring Carl June for developing CAR-T therapy (the world’s first gene-based cancer therapy), Sharon Terry for inciting the movement to build systems for individuals to access and share health data, and Feng Zhang for spearheading the development of optogenetics and CRISPR. For the Pioneer Award, PMWC will be recognizing George Yancopoulos for developing foundational technologies designed to invent groundbreaking therapies.

Date & Agenda

When: January 20th at 6:00-8:00pm

Where: PMWC Venue – Track 2

Suggested dress: Cocktail attire

RSVP AND SEPARATE REGISTRATION REQUIRED. SEND INQUIRIES BY 1/4/19 TO [email protected] TO SEE IF SPACE IS AVAILABLE.
Luminary Pioneer Company Competition

Past Luminary Award Recipients

Emmanuelle Charpentier

2018

Pioneered the CRISPR-CAS9 Genome Editing Technology

Jennifer Doudna

2017

Pioneered the Groundbreaking Crispr-Cas9 Genome Editing Technology

Edward F. Chang

2017

Pioneer in Human Brain Circuit Mapping to Advance Precision Neuropathology

Roger Perlmutter

2016

Expedited Development of Groundbreaking Therapies

Laura Esserman

2016

Breast Cancer Treatment Paradigm Shifter

Ron Davis

2015

Developed R-loop Technique of Electron Microscopy

Jay Flatley

2014

Established Illumina as the leader in sequence technology

Janet Woodcock

2013

FDA Director, fast-tracked targeted drugs through FDA approval

Brian Druker

2012

Co-inventor, blockbuster drug, Gleevec

George Church

2011

Contributions to the sequencing of genomes and interpreting such data; In Neuroscience he established a “functional connectome”

Lee Hood

2010

Inventions included the automated DNA sequencer and a tool for synthesizing DNA

Past Pioneer Award Recipients

Ronald Levy

2018

Pioneered the concept of antibodies being used as personalized anticancer drugs

Sir John Bell

2018

Leading Genetic and Genomic Research Initiatives that Enable Precision Medicine in the UK and Globally

Alan Ashworth

2018

Co-discovered the BRCA2 gene mutation and made discoveries leading to PARP inhibition in breast and other cancers

James Allison

2017

Pioneered Cancer Immunotherapy Through Discovery of the Immune Checkpoint Blockade

Steve Quake

2017

Steve Quake has pioneered innovative approaches to biological measurement

Irv Weissman

2016

Pioneer in Regenerative Medicine & Cancer Stem Cells

Ralph Snyderman

2016

Widely recognized as “Father of Personalized Medicine”

Craig Venter

2015

1st Draft Human Gen., 1st Complete Diploid Human Gen., and 1st Synth. Bact. Cell

Dennis Lo

2015

Discovered That An Unborn Fetus Releases Fetal DNA Into Maternal Plasma

Jonathan K.C. Knowles

2015 – UK

Personalized Medicine Leader in both Academia and the Pharmaceutical Industry

Yuet Wain Kan

2014

The first to establish that a single DNA mutation could lead to a human disease, and the first to diagnose a human disease by using DNA

Michael Hayden

2014 – Israel

Developer, First Predictive Test for Huntington’s Disease

Kim Popovits

2013 – Israel

Launched both earliest genetically-targeted therapy and molecular diagnostic assay

Most Promising Company Award

The PMWC Most Promising Company Competition has accompanied PMWC since 2009 with the goal to assist “rising star” startups in Diagnostics, Therapeutics, and Health Tech to increase their visibility, provide them with a platform to present to a group of leading investors, as well as to potential clients and partners so they can succeed on their path forward.

Abreos Biosciences

Abreos Biosciences is a precision medicine company in San Diego, CA developing laboratory-based and near-patient tests for precision dosing of biologic drugs. Abreos has cultivated a diverse portfolio of Veritope™ tests that allow for direct monitoring of blood concentrations of monoclonal antibody drugs (novel or biosimilar). Website: abreos.com

Immusoft

Immusoft’s mission is re-program patient cells into miniature drug factories that engraft and survive for decades in the body. Website: immusoft.com

Two Pore Guys

Two Pore Guys

Two Pore Guys created a solid-state nanopore-based diagnostic testing platform that can detect nucleic acids, proteins and other analytes with comparable performance of lab equipment, in a glucometer-style system. Website: twoporeguys.com

Gritstone Oncology

Gritstone Oncology

Every patient’s tumor is molecularly unique – Gritstone Oncology deploys a proprietary tumor antigen prediction model based upon patient tumor sequencing/mass spectrometry to deliver antigens as personalized therapeutic vaccine alongside checkpoint inhibitors. Website: gritstoneoncology.com

healthmyne

HEALTHMYNE

HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. Website: healthmyne.com

insilico

INSILICO MEDICINE

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Website: insilicomedicine.com

accel-diag

ACCEL DIAGNOSTICS

AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests at any time and any place. The patented pScreen™ platform technology employs a single-use blood test the size of a credit card in tandem with a smartphone application to quickly detect disease-specific biomarker levels. Website: acceldx.com

t2-biosystems

T2 BIOSYSTEMS

T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. Their new class of clinical diagnostics powered by T2MR is the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. IPO, Aug. 2014. Website: t2biosystems.com

elminda

ELMINDA

ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks. Website: elminda.com

horizon

HORIZON DISCOVERY

Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer. IPO, March 2014. Website: horizondiscovery.com

quanta-life

QUANTALIFE

QuantaLife provides advanced genetic analysis systems for research. QuantaLife has commercialized the Droplet Digital™ (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost-effective, high-resolution platform available for the validation of next-generation sequencing discoveries. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests. Acquired by Bio-Rad, October 2011. Website: bio-rad.com

Applied-I1

APPLIED IMMUNE TECHNOLOGIES

Applied Immune Technologies’ (AIT) core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. Acquired by Adicet Bio, January 2016. Website: tcrl.co.il

BHL

BOSTON HEART LAB

Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. The Company’s goal is to predict, prevent, manage and reverse cardiovascular disease by improving patient assessment and management. Acquired by Eurofins Scientific, December 2014. Website: bostonheartdiagnostics.com

Testimonials

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!